Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
NOR-SWITCH trial shows switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with inflixima...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
